TABLE 2.
Study characteristics
| Author | No. of patients | Median follow up (mths) | RT technique | RT dose (Gy) | Pelvic RT (%) | ADT (%) | Grade 2 GI toxicity (%) | Grade 3 GI toxicity (%) | Grade 2 GU toxicity (%) | Grade 3 GU toxicity (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Ataman30 | 377 | 42 | 2D | 70.0 | 17% | 50%+ | 9.8% | 0.3% | 15.9% | 3.4% |
| Beckendorf8 | 256 | 57 | 3D | 70.0 | 0% | 0% | 14.4% | 2.0% | 9.8% | 2.6% |
| 80.0 | 19.6% | 5.9% | 17.6% | 2.0% | ||||||
| Bolla31 | 970 | 77 | 3D | 70.0 | 100% | 100% | NR | 0.6% | NR | 2.2% |
| De Meerleer36 | 133 | 36 | IMRT | 76.0 | 0% | 59% | 17.3% | 0.8% | 21.8% | 3.0% |
| Dearnaley9 | 421 | 60 | 3D | 64.0 | 0% | 100% | 24.0% | 6.0% | 8.0% | 2.0% |
| 422 | 74.0 | 33.0% | 10.0% | 11.0% | 4.0% | |||||
| Horwitz32 | 1521 | 135 | 2D | 70.0# | 100% | 100% | 16.2% | 1.8% | 19.1% | 4.7% |
| Kupelian26 | 770 | 45 | IMRT | 77.0^^^ | 0% | 60% | 6%^ | 2%^ | 7%^ | 0.2%^ |
| Lawton33 | 467 | 97 | 2D | 70.0# | 100% | 0% | NR | 4.3% | NR | 8.8% |
| 477 | 97 | 100% | NR | 3.6% | NR | 7.3% | ||||
| 231 | 83 | 0% | NR | 4.3% | NR | 8.2% | ||||
| 223 | 83 | 100% | NR | 2.2% | NR | 7.6% | ||||
| Michalski35 | 75 | 114 | 3D | 68.4 | 0% | 12% | 9.3% | 1.6% | 24.0% | 1.6% |
| 97 | 103 | 73.8 | 51% | 7.2% | 0.0% | 21.6% | 2.9% | |||
| 103 | 105 | 77.2@ | 44% | 10.7% | 1.8% | 18.4% | 4.2% | |||
| 115 | 88 | 74.0 | 39% | 10.4% | 2.4% | 28.7% | 4.7% | |||
| 118 | 72 | 78.0 | 20% | 25.4% | 5.4% | 22.9% | 5.5% | |||
| Peeters10 | 331 | 51 | 3D | 68.0 | 0% | 22% | 27%^ | 4%^ | 41%^ | 12%^ |
| 333 | 78.0 | 21% | 32%^ | 5%^ | 39%^ | 13%^ | ||||
| Pollack11 | 148 | 60 | 2D | 70.0 | 0% | 0% | 11.5% | 0.7% | 8.8% | 1.4% |
| 151 | 3D | 78.0 | 25.5% | 6.7% | 12.8% | 2.7% | ||||
| Quon27 | 97 | 39 | IMRT | 77.0^^^ | 100% | 100% | 6.5% | 0.0% | 9.7% | 4.3% |
| Roach34 | 638 | 60 | 2D | 70.2 | 0% | 100% | NR | 0.8% | NR | 2.4% |
| 641 | 100% | 1.9% | 2.5% | |||||||
| Slater24 | 643 | 43 | PBRT | 74.5 (GyE) | 50% | NR | 21%^^ | 0%^^ | 5.7%^^ | 0.3%^^ |
| Vesprini25 | 89 | 52 | IMRT | 72.0^^^ | 0% | NR | 7.9% | 1.1% | 14.6% | 0.0% |
| Vora37 | 271 | 62 | 3D | 68.4 | 0% | 18% | 16.2% | 0.7% | 21.4% | 4.8% |
| 145 | 48 | IMRT | 75.6 | 0% | 30% | 24.1% | 1.4% | 28.3% | 5.5% | |
| Zapatero38 | 306 | 64 | 3D | 78.0 | 36% | 95% | 10.1% | NR | 14.7% | NR |
| Zeitman12 | 196 | 66 | PBRT | 70.2 (GyE) | 0% | 0% | 8.2% | 0.5% | 19.4% | 1.5% |
| 195 | 79.2 (GyE) | 17.4% | 0.5% | 20.4% | 0.5% | |||||
| Zelefsky39 | 363 | 42 | 3D | 70.2 | 0% | 29% | 7%^ | 0%^ | 8%^ | NR |
| 380 | 75.6 | 16%^ | 1.6%^ | 15%^ | NR | |||||
| Zilli28 | 82 | 52 | IMRT | 78.4^^^ | 0% | 13% | 4.9% | 1.2% | 7.3% | 1.2% |
RT = radiotherapy; GI = gastrointestinal/bowel; GU = genitourinary/bladder; Gy = gray; GyE = gray equivalent; IMRT = intensity-modulated radiotherapy; PBRT = proton radiotherapy; ADT = androgen deprivation therapy; NR = not reported
*
median dose;
**
mean dose;
#
approximate dose;
^
actuarial incidence at 5 years;
^^
actuarial incidence at 3 years;
^^^
bioequivalent dose;
@
median PTV dose.